At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
Tirzepatidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate Tirzepatide Concentrations in Breastmilk Following Administration of Single Dose of Tirzepatide by Subcutaneous Injection in Healthy Lactating Females
In Brief
A Phase 1 clinical trial evaluating Tirzepatide for Healthy. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The main purpose of this study was to look if the study drug, tirzepatide, gets into the breastmilk and, if yes, how long it takes the body to get rid of it from the breastmilk. The study drug was given as a single injection under the skin in healthy lactating females. For each participant, the total duration of the study was approximately 8 weeks, including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
Enrollment StartJul 2023
First PostedAug 2023
Primary CompletionMar 2024
TodayJul 2026
First PostedAug 7, 2023
Enrollment StartJul 31, 2023
Primary CompletionMar 12, 2024
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 2.9 years ago
Interventions
Tirzepatidedrug
Administered SC